tbuckley/cabot-search huggingface dataset:
Role of allo-HCT in "nonclassical" MPNs and MDS/MPNs: recommendations from the PH&amp;G Committee and the CMWP of the EBMT
Authors: Nicola Polverelli, Juan Carlos Hernandez-Boluda, Francesco Onida, Carmelo Gurnari, Kavita Raj, Tomasz Czerw, Michelle Kenyon, Marie Robin, Katja Sockel, Annalisa Ruggeri, Isabel Sánchez-Ortega, Daniel A. Arber, Luca Arcaini, Fernando Barroso Duarte, Giorgia Battipaglia, Yves Chalandon, Fabio Ciceri, Nicholas C.P. Cross, Joanna Drozd-Sokolowska, Vaneuza Araújo Moreira Funke, Nico Gagelmann, Naseema Gangat, Jason Gotlib, Paola Guglielmelli, Claire N. Harrison, Gabriela S Hobbs, Tania Jain, Joseph D. Khoury, Jean-Jacques Kiladjian, Nicolaus Kröger, Luca Malcovati, Massimo Martino, Ruben Mesa, Attilio Orazi, Eric Padron, Francesca Palandri, Francesco Passamonti, Mrinal M. Patnaik, Naveen Pemmaraju, Deepti H. Radia, Andreas Reiter, Domenico Russo, Christof Scheid, Ayalew Tefferi, Alessandro M. Vannucchi, Daniel Howard Wiseman, Ibrahim Yakoub-Agha, Donal P McLornan
Journal: Blood (2025)

'Non-classical' Myeloproliferative Neoplasms (MPNs) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPNs) represent a heterogeneous group of malignancies characterized by a wide range of clinical manifestations. Unlike classical MPNs, there is no standardized management approach for these conditions, particularly concerning the indications for and management of allogeneic hematopoietic cell transplantation (HCT). To address this gap, the EBMT Practice Harmonization and Guidelines (PH&G) Committee and the Chronic Malignancies Working Party (CMWP) have collaborated to develop shared guidelines aimed at optimizing the selection and management of patients with these rare forms of neoplasms. A comprehensive review of the literature from the publication of the revised 4th edition of the (2016) WHO classification onward was conducted. A multidisciplinary group of experts in the field convened to produce this document, which was developed through multiple rounds of draft circulation. Key recommendations include the early identification of potential transplant candidates, particularly in cases of chronic neutrophilic leukemia (CNL), chronic eosinophilic leukemia (CEL) / CEL, not otherwise specified (CEL-NOS), myeloid/lymphoid neoplasm with eosinophilia and tyrosine kinase gene fusions (MLN-TK) with FGFR1, JAK2, ABL1, and FLT3 rearrangements, MDS/MPN with neutrophilia / atypical chronic myeloid leukemia (aCML), and MDS/MPN, NOS. For patients with MPN, NOS / MPN unclassifiable, standard recommendations for myelofibrosis (MF) should be applied. Similarly, in MDS/MPN with thrombocytosis, transplantation is recommended based on established MDS guidelines. Given the current lack of robust evidence, this document will serve as a valuable resource to guide future research activities, providing a framework for addressing critical unanswered questions and advancing the field.
Fertility Preservation in People With Cancer: ASCO Guideline Update
Authors: H. Irene Su, Christina Lacchetti, Joseph Letourneau, Ann H. Partridge, Rubina Qamar, Gwendolyn P. Quinn, Joyce Reinecke, James F. Smith, Megan Tesch, W. Hamish Wallace, Erica T. Wang, Alison W. Loren
Journal: Journal of Clinical Oncology (2025)

To provide updated fertility preservation (FP) recommendations for people with cancer. A multidisciplinary Expert Panel convened and updated the systematic review. One hundred sixty-six studies comprise the evidence base. People with cancer should be evaluated for and counseled about reproductive risks at diagnosis and during survivorship. Patients interested in or uncertain about FP should be referred to reproductive specialists. FP approaches should be discussed before cancer-directed therapy. Sperm cryopreservation should be offered to males before cancer-directed treatment, with testicular sperm extraction if unable to provide semen samples. Testicular tissue cryopreservation in prepubertal males is experimental and should be offered only in a clinical trial. Males should be advised of potentially higher genetic damage risks in sperm collected soon after cancer-directed therapy initiation and completion. For females, established FP methods should be offered, including embryo, oocyte, and ovarian tissue cryopreservation (OTC), ovarian transposition, and conservative gynecologic surgery. In vitro maturation of oocytes may be offered as an emerging method. Post-treatment FP may be offered to people who did not undergo pretreatment FP or cryopreserve enough oocytes or embryos. Gonadotropin-releasing hormone agonist (GnRHa) should not be used in place of established FP methods but may be offered as an adjunct to females with breast cancer. For patients with oncologic emergencies requiring urgent oncologic therapy, GnRHa may be offered for menstrual suppression. Established FP methods in children who have begun puberty should be offered with patient assent and parent/guardian consent. The only established method for prepubertal females is OTC. Oncology teams should ensure prompt access to a multidisciplinary FP team. Clinicians should advocate for comprehensive FP services coverage and help patients access benefits.Additional information is available at www.asco.org/survivorship-guidelines.
NKG2D-mediated cytotoxicity of CD4 cytotoxic T cells in multiple myeloma
Authors: Sojeong Kim, Jeong-Eun Kwak, June-Young Koh, Ji Eun Lee, Hye Won Kook, Minchae Kim, Haerim Chung, Yuri Kim, Soo Jeong Kim, Jin Seok Kim, June-Won Cheong, Min Goo Lee, Hoyoung Lee, Su-Hyung Park, Eui-Cheol Shin, Saeam Shin, Sun Och Yoon, Il-Kyu Choi, Jeong Seok Lee, Hyunsoo Cho
Journal: Blood (2025)
Reply to: Challenges in Assessing Response in Clinical Trials for Neurofibromatosis Type 1 Plexiform Neurofibromas
Authors: Christopher L. Moertel, Angela C. Hirbe, Laura J. Klesse, P. Leia Nghiemphu, Dusica Babovic-Vuksanovic, Timothy R. Gershon
Journal: Journal of Clinical Oncology (2025)
A Pilot Study to Capture Provider Perspectives on Clinically Relevant Effects in Thoracic Transplant Trials
Authors: Edward Cantu, Dane Isenberg, Abigail Marquis, Alyster Alcudia, Sophia Yusuf, Aya Saleh, Allie Raevsky, Fan Li, Michael O Harhay
Journal: American Journal of Respiratory and Critical Care Medicine (2025)
Deconvoluting the interplay of innate and adaptive immunity in BCG-induced nonspecific and TB-specific host resistance
Authors: Kerry L. Hilligan, Patricia A. Darrah, Robert A. Seder, Alan Sher
Journal: The Journal of Experimental Medicine (2025)

BCG is the oldest vaccine in continuous use. While current intradermal vaccination regimens confer limited protection outside the context of pediatric extrapulmonary tuberculosis (TB), promising new data indicate that when administered mucosally or intravenously at a higher dose, BCG can induce sterilizing immunity against pulmonary TB in nonhuman primates. BCG is also known to promote nonspecific host resistance against a variety of unrelated infections and is a standard immunotherapy for bladder cancer, suggesting that this innate immune function may contribute to its protective role against TB. Here, we propose that both the mycobacterial-specific and off-target effects of BCG depend on the interplay of adaptive and innate cells and the cytokines they produce, and that the elucidation of this interaction should be a major strategy in the development of more effective BCG-based vaccines and immunotherapies.
Phenotypes of Myocardial Dysfunction on Serial Echocardiography and CMR in Women With Early-Stage Breast Cancer
Authors: Flora Huang, Kate Rankin, Maala Sooriyakanthan, Marisa Signorile, Chun-Po Steve Fan, Babitha Thampinathan, Thomas H Marwick, Nichanan Osataphan, Christopher Yu, C Anne Koch, Eitan Amir, Kate Hanneman, Husam Abdel-Qadir, Bernd J Wintersperger, Paaladinesh Thavendiranathan
Journal: JACC. Cardiovascular imaging (2025)

Understanding phenotypic variations in left ventricular (LV) dysfunction during cancer therapy may allow for tailored surveillance and prevention. The study sought to determine LV dysfunction phenotypes during cancer therapy and their interrelated-ness and association with cancer therapy-related cardiac dysfunction (CTRCD), myocardial tissue changes, and blood biomarkers. This is a secondary analysis of the EMBRACE-MRI (Evaluation of Myocardial Changes During BReast Adenocarcinoma Therapy to Detect Cardiotoxicity Earlier With MRI) study in which women with early-stage HER2+ breast cancer were recruited prospectively. High-sensitivity troponin I, B-type natriuretic peptide, and echocardiography were obtained pre-anthracycline and every 3 months with measurement of systolic and diastolic function and left atrial reservoir strain (LARS). Cardiac magnetic resonance (CMR) was performed at baseline and follow-ups with quantification of myocardial T1, T2, and extracellular volume (ECV). Diastolic dysfunction (DD) was graded using American Society of Echocardiography guidelines ("conventional") and regraded by replacing left atrial volume with LARS <24% ("modified"). Relative reduction in global longitudinal strain (GLS) >15% was considered "worsening GLS," and CTRCD was defined using CMR-derived left ventricular ejection fraction. Among 136 women (51.1 ± 9.2 years), CTRCD developed in 37 of 136 (27%) and worsening GLS in 53 of 126 (42%) with analyzable studies. Incident DD occurred in 25 (19.4%) of 129 and 19 (14.4%) of 132 patients by conventional and modified grading, respectively. Using LARS improved the ability to classify DD. Transition state analysis demonstrated that the first abnormal state during cancer therapy could be worsening GLS, DD, CTRCD, or a combination. A greater proportion of patients who first transition to DD vs worsening GLS developed subsequent CTRCD (5 of 8 [63%]) vs 7 of 39 [18%]). Worsening DD was associated with higher odds of subsequent CTRCD (OR: 20.9, 95% CI: 3.4-129.5) vs worsening GLS (OR: 4.9, 95% CI: 2.6-9.4). DD was significantly associated with radiation dose and ECV but not with blood biomarkers. Patients receiving breast cancer therapy can develop significant GLS change, DD, or CMR-defined CTRCD that can occur in isolation, concurrently, or sequentially. Development of DD is associated with ECV and higher risk for subsequent CTRCD. (Evaluation of Myocardial Changes During BReast Adenocarcinoma Therapy to Detect Cardiotoxicity Earlier With MRI [EMBRACE-MRI]; NCT02306538).
Prognostic Relevance and Lower Limit of the Reference Range of Left Ventricular Global Longitudinal Strain
Authors: Daniel A Morris, Chung-Lieh Hung, Tor Biering-Sørensen, Tatiana Kuznetsova, Erwan Donal, Wojciech Kosmala, Masaaki Takeuchi, Roberto Lang, Marijana Tadic, Chun-Yan Ma, Evgeny Belyavskiy, Henryk Dreger, Matthias Schneider-Reigbert, Athanasios Frydas
Journal: JACC. Cardiovascular imaging (2025)

The lower limit of the reference normal range (LLN) of left ventricular global longitudinal strain (GLS) for each ultrasound software vendor and its prognostic relevance in the elderly and in asymptomatic patients at risk for heart failure (HF) remain uncertain. In this study, the authors sought to validate the LLN of GLS for each ultrasound software vendor and its prognostic relevance in the elderly and in asymptomatic patients at risk for HF. To identify the LLN of GLS with the use of 2-dimensional speckle-tracking transthoracic echocardiography, a meta-analysis of studies including healthy subjects was conducted, followed by a validation study in a large cohort of healthy subjects. To validate the prognostic relevance of the LLN of GLS, 2 validation cohort studies were carried out, including elderly subjects aged ≥80 years and asymptomatic ambulatory patients with preserved left ventricular ejection fraction at risk for HF. The meta-analysis, which included 47 studies with a total of 23,208 healthy adult subjects, identified the LLN for GLS at 16% (absolute value) across various ultrasound software vendors, including EchoPac, TomTec, and QLab. In the validation cohort study, which included 2,217 healthy adult subjects, a GLS cutoff of 16% was also identified as the LLN. Concerning the prognostic relevance of the LLN of GLS, a value of GLS <16% was significantly associated with HF hospitalization in asymptomatic ambulatory patients at risk for HF (n = 667; OR within 6 years: 5.1 [95% CI: 1.5-17.0]) and in elderly subjects (n = 159; OR within 2 years: 3.1 [95% CI: 1.1-8.8]). This clinical validation study provides important clinical data concerning the LLN of GLS (identified and validated at 16%) and its prognostic relevance in the elderly and in asymptomatic ambulatory patients at risk for HF.
Trained immunity-based mucosal immunotherapies for the prevention of respiratory infections
Authors: Luna Minute, Karla Montalbán-Hernández, Laura Bravo-Robles, Laura Conejero, Salvador Iborra, Carlos Del Fresno
Journal: Trends in Immunology (2025)

The devastating impact of respiratory infections demonstrates the critical need for novel prophylactic vaccines. In this opinion article, we advocate for bacterial immunotherapies as a complementary tool in our fight against respiratory infections. These immunotherapies can activate a wide spectrum of immunological mechanisms, with trained immunity (TI) being particularly significant. This phenomenon has led to the concept of trained immunity-based vaccines (TIbVs), which represent a novel approach in vaccinology. We discuss examples of TIbVs, including the tuberculosis vaccine Bacille Calmette-Guérin (BCG) and the polybacterial immunotherapy MV130. From our viewpoint, illustrating the mode of action and clinical evidence supports the proposal that TIbVs should be considered as next-generation vaccines to confer protection against a wide range of respiratory infections.
Surveillance for Metastasis in Low-Risk Uveal Melanoma Patients: Need for Optimization
Authors: Adrienne Delaney, Yağmur Seda Yeşiltaş, Emily C Zabor, Arun D Singh
Journal: Ophthalmology (2025)

To evaluate the effectiveness of surveillance protocols utilizing hepatic ultrasonography (US) at 6-month intervals to detect metastasis and determine its impact on overall survival (OS) in low-risk uveal melanoma (UM) patients. Retrospective Cohort Study SUBJECTS: 144 consecutive patients with Class 1 (low risk) primary UM were enrolled. All patients had negative baseline systemic staging following which they underwent systemic surveillance either with hepatic US at 6-month intervals (standard protocol, SP) or enhanced protocol (EP) utilizing high frequency (US every 3 months) or enhanced modality (EM, hepatic computed tomography/magnetic resonance imaging). Largest diameter of largest hepatic metastasis (LDLM), number of hepatic metastatic lesions, time to detection of metastasis (TDM), and OS. Median follow-up time for those still alive (134, 10 patients died from any cause) was 50.6 months (IQR: 28.6-76.1). Surveillance was done with SP in the majority (101 [70%]) and EP in 43[30%]). A total of 834 US scans were performed (median 5.0 [IQR: 3.0, 8.0])) that led to detection of metastasis in 6 patients by SP in the majority (5/6) and EP in 1/6. The median LDLM at detection was 2.8 cm. Only tumor largest basal diameter was significantly associated with increased hazard of metastasis (HR 1.33 [95% CI, 1.04-1.70]; p= 0.022) whereas age, tumor thickness, and PRAME status were not. All patients were treated for metastasis (liver directed 1 [17%], systemic therapy 5 [83%]). The vast majority of patients with UM predicted to have low risk of metastasis do not develop metastasis by 5 years (96%). Surveillance protocols in such patients have very low yield and their impact on survival cannot be assessed. Our study demonstrates the need for further risk refinement of low-risk UM patients to better identify at-risk individuals. Currently used surveillance protocols need to be optimized.
Photo-responsive self-expanding catheter with photosensitizer-integrated silicone-covered membrane for minimally invasive local therapy in malignant esophageal cancer
Authors: Dae Sung Ryu, Hyeonseung Lee, Seung Jin Eo, Ji Won Kim, Yuri Kim, Seokin Kang, Jin Hee Noh, Sanghee Lee, Jung-Hoon Park, Kun Na, Do Hoon Kim
Journal: Biomaterials (2025)
"Safety Assessment of Aqueous Humor Liquid Biopsy in Retinoblastoma: A Multicenter Study of 1,203 Procedures”
Authors: Douglas Chigane, Drishti Pandya, Muskaan Singh, Brianne Brown, Michelle Lin, Liya Xu, Andrew W Stacey, Alyssa C Bonnell, G Baker Hubbard, Hans Grossniklaus, Alison H Skalet, Kellyn N Bellsmith, Sara E Lally, Margarida Simão-Rafael, Cristina Jou Muñoz, Jaume Català-Mora, Denis Malaise, Livia Lumbroso-Le Rouic, Alexandre Matet, Guillermo L Chantada, Nathalie Cassoux, Carol L Shields, Jesse L Berry
Journal: Ophthalmology (2025)
The revolutionary role of placental derivatives in biomedical research
Authors: Saeid Moghassemi, Saba Nikanfar, Arezoo Dadashzadeh, Maria João Sousa, Yuting Wan, Fengxuan Sun, Arthur Colson, Sven De Windt, Lena Kwaspen, Marc Kanbar, Keyvan Sobhani, Jie Yang, Hanne Vlieghe, Yongqian Li, Frédéric Debiève, Christine Wyns, Christiani A Amorim
Journal: Bioactive Materials (2025)
Targeting the JAK2–STAT3–UCHL3–ENO1 axis suppresses glycolysis and enhances the sensitivity to 5-FU chemotherapy in TP53-mutant colorectal cancer
Authors: Haisong Xin, Zitong Zhao, Shichao Guo, Ruoxi Tian, Liying Ma, Yang Yang, Lianmei Zhao, Guanglin Wang, Baokun Li, Xuhua Hu, Yongmei Song, Guiying Wang
Journal: Acta Pharmaceutica Sinica B (2025)
Dual role of interferon-gamma in the response of melanoma patients to immunotherapy with immune checkpoint inhibitors
Authors: Piotr Wawrzyniak, Mariusz L. Hartman
Journal: Molecular Cancer (2025)

Abstract Interferon-gamma (IFN-γ) is a cytokine produced mainly by immune cells and can affect cancer cells by modulating the activity of multiple signaling pathways, including the canonical Janus-activated kinase/signal transducer and activator of transcription (JAK/STAT) cascade. In melanoma, IFN-γ can exert both anticancer effects associated with cell-cycle arrest and cell death induction and protumorigenic activity related to immune evasion leading to melanoma progression. Notably, IFN-γ plays a crucial role in the response of melanoma patients to immunotherapy with immune checkpoint inhibitors (ICIs), which are currently used in the clinic. As these agents target programmed death-1 (PD-1) and its ligand (PD-L1), cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) and lymphocyte-activation gene 3 (LAG-3), they are designed to restore the antimelanoma immune response. In this respect, IFN-γ produced by cells in the tumor microenvironment in response to ICIs has a beneficial influence on both immune and melanoma cells by increasing antigen presentation, recruiting additional T-cells to the tumor site, and inducing direct antiproliferative effects and apoptosis in melanoma cells. Therefore, IFN-γ itself and IFN-γ-related gene signatures during the response to ICIs can constitute biomarkers or predictors of the clinical outcome of melanoma patients treated with ICIs. However, owing to its multifaceted roles, IFN-γ can also contribute to developing mechanisms associated with the acquisition of resistance to ICIs. These mechanisms can be associated with either decreased IFN-γ levels in the tumor microenvironment or diminished responsiveness to IFN-γ due to changes in the melanoma phenotypes associated with affected activity of other signaling pathways or genetic alterations e.g., in JAK , which restricts the ability of melanoma cells to respond to IFN-γ. In this respect, the influence of IFN-γ on melanoma-specific regulators of the dynamic plasticity of the cell phenotype, including microphthalmia-associated transcription factor (MITF) and nerve growth factor receptor (NGFR)/CD271 can affect the clinical efficacy of ICIs. This review comprehensively discusses the role of IFN-γ in the response of melanoma patients to ICIs with respect to its positive influence and role in IFN-γ-related mechanisms of resistance to ICIs as well as the potential use of predictive markers on the basis of IFN-γ levels and signatures of IFN-γ-dependent genes.
Understanding gold nanoparticles and their attributes in ovarian cancer therapy
Authors: Rishabh Aggarwal, Afsana Sheikh, Masheera Akhtar, Mohammed Ghazwani, Umme Hani, Amirhossein Sahebkar, Prashant Kesharwani
Journal: Molecular Cancer (2025)

Ovarian cancer is one the deadliest disease wherein the survival rate is very low. Despite of advances in medical sciences, researches are still at the stage of infancy where patients are succumbing to this malignancy. Multidrug resistance, toxicity, mode of treatment related issues like catheter related complication poises a number of challenges to scientists worldwide. Novel therapy is now thus being focussed to sensitive the cells more towards the treatment. Gold nanoparticles (Au NPs), known for their high biocompatibility, and strong optical and magnetic responses, have emerged as promising agents for both the diagnosis and treatment of ovarian cancer. Owing to physical characteristics, AuNPs may be used as adjuvants in bioimaging, radiotherapy and fluorescence imaging. As a result, these characteristics substantially support AuNPs in biological domains. In addition to their therapeutic potential, Au NPs exhibit strong surface plasmon resonance (SPR) properties, enhancing imaging techniques for early detection of ovarian tumors. Furthermore, chemical properties such as Magnetic Resonance and Imaging Properties, X-ray imaging property, Two-photon or multiphoton imaging, and Optical coherence tomography (OCT) imaging properties enhance the use of Au NPs in diagnosis. This paper highlights the properties, targeting potential and diagnosis and treatment of ovarian cancer by Au NPs has been discussed.
Advances in diagnosis, classification, and management of pain in Parkinson's disease
Authors: Michele Tinazzi, Marialuisa Gandolfi, Carlo Alberto Artusi, Kirsty Bannister, Katarina Rukavina, Christine Brefel-Courbon, Daniel Ciampi de Andrade, Santiago Perez-Lloret, Veit Mylius
Journal: The Lancet Neurology (2025)
Intravenous thrombolysis before endovascular treatment versus endovascular treatment alone for patients with large vessel occlusion and carotid tandem lesions: individual participant data meta-analysis of six randomised trials
Authors: Fabiano Cavalcante, Kilian Treurniet, Johannes Kaesmacher, Manon Kappelhof, Roman Rohner, Pengfei Yang, Jianmin Liu, Kentaro Suzuki, Bernard Yan, Theodora van Elk, Lei Zhang, Maarten Uyttenboogaart, Wenjie Zi, Derraz Imad, Yongwei Zhang, Papagiannaki Chrysanthi, Hal Rice, Pengfei Xing, Kazumi Kimura, Peter Mitchel, Philipp Bücke, Changwei Guo, Vincent Costalat, Romain Bourcier, Daan Nieboer, Hester Lingsma, Jan Gralla, Urs Fischer, Yvo B Roos, Charles B Majoie
Journal: The Lancet Neurology (2025)
No health without aid and development
Authors: Charlotte Hanlon, Martyn Pickersgill, Seth Amanfo, Harry Campbell, Anna Chiumento, Jeff Collin, Michael Eddleston, Liz Grant, Ewen Harrison, Aisha Holloway, Sumeet Jain, Stephen Lawrie, Angus Macbeth, Chelsea Morroni, Lotte Segal, Nadine Seward, Rosie Stenhouse, Robert C Stewart, Harish Nair
Journal: The Lancet Global Health (2025)